|Bid||9.60 x 1000|
|Ask||0.00 x 1100|
|Day's range||9.18 - 9.73|
|52-week range||9.18 - 21.05|
|Beta (5Y monthly)||1.68|
|PE ratio (TTM)||N/A|
|Earnings date||04 Dec 2023 - 08 Dec 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.25|
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (NASDAQ: CDMO) hasn't been a very lively investment in recent days. According to data compiled by S&P Global Market Intelligence, the specialty healthcare company's stock was down 17% week to date as of early Friday morning. Avid Bioservices, a contract developer and manufacturer of biologics, released its fiscal 2023 fourth-quarter results after market hours on Wednesday.
Shares of Avid Bioservices (NASDAQ: CDMO) were down more than 12% Thursday afternoon after falling as much as 17% earlier in the day. The drop came after the biologics contract development and manufacturing organization (CDMO) released fourth-quarter and full-year fiscal 2023 earnings. Avid's stock is down more than 2% so far this year.